Objective
Alternative splicing (AS) is a highly regulated process that is essential for creating the protein diversity required for correct cell-type specification. Misregulation of AS programs can lead to cellular dysfunction, developmental problems and disease, such as cancer. Understanding how alternative splicing is regulated during development and disease is therefore capital.
Recent advances in the field have shown that, not only does AS regulation rely on the recruitment of various splicing factors to the pre-mRNA, but other phenomena such as RNA Polymerase II elongation rate, histone post-translational modifications or long non-coding RNAs have been shown to regulate this process.
I hypothesize that transcriptional enhancers also play a critical role in the establishment and maintenance of cell-type-specific AS programs. I propose to study the effect of enhancer activation on AS regulation during the epithelial-to-mesenchymal transition (EMT), an important physiological process involved in tumour metastasis and cancer recurrence. Using genome-wide studies, I will map and physically link activated enhancers to intragenic regions of alternatively spliced genes over the course of the EMT in human mammary epithelial cells. I will then employ a candidate-based approach to tease apart the multiple processes through which enhancer activation can regulate splicing patterns, and to discover new enhancer-linked regulators implicated in the AS process.
Long-term, this project aims to establish a direct functional link between enhancer activation and alternative splicing during development, with the ultimate ambition of being able to modify AS patterns through the regulation of enhancers. This study will yield results expected to have important implications for the understanding of how cancer-specific splicing programs are established and maintained and have the potential to discover innovative targets to revert EMT and in this way reduce tumour metastasis and cancer progression.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences neurobiology
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences clinical medicine oncology
- medical and health sciences basic medicine pathology
- natural sciences biological sciences genetics RNA
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2016
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
75794 PARIS
France
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.